--- title: "U.S. stock market midday update: Galectin Therap up 16.74%, active funds but no news catalyst" type: "News" locale: "en" url: "https://longbridge.com/en/news/292651995.md" description: "Galectin Therap rose 16.74%; NextCure rose 219.95%, with a transaction volume of USD 764 million; Biogen fell 8.57%, with a transaction volume of USD 274 million; AbbVie fell 1.07%, with a transaction volume of USD 271 million; Amgen fell 1.05%, with a market value of USD 192.5 billion" datetime: "2026-07-14T15:53:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292651995.md) - [en](https://longbridge.com/en/news/292651995.md) - [zh-HK](https://longbridge.com/zh-HK/news/292651995.md) --- # U.S. stock market midday update: Galectin Therap up 16.74%, active funds but no news catalyst **U.S. Stock Market Midday Update** Galectin Therap rose 16.74%. There are no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news **Stocks with High Trading Volume in the Industry** NextCure rose 219.95%. Based on recent news, 1. On July 14, NextCure reached an all-stock merger agreement with Avere Therapeutics, expected to be completed in the second half of 2026. After the merger, Hansoh Pharmaceutical will hold 30%-40% equity in the merged entity. This news significantly boosted NextCure's stock price. 2. On July 14, NextCure announced it secured $3.2 million in private financing for the development of AVR-001, an experimental drug targeting inflammatory diseases. The financing news further boosted market confidence, driving the stock price up. 3. On July 14, NextCure shareholders will be entitled to 90% of any licensing or other transaction proceeds within two years after the merger. This positive news attracted a large number of investors, leading to a significant increase in stock price. The biotechnology sector has performed strongly recently, with investors focusing on new drug development progress. Biogen fell 8.57%, with increased trading volume. Based on recent key news: 1. On July 14, Biogen's Alzheimer's drug diranersen failed to meet primary endpoints in a mid-stage study, leading to a drop in stock price. Although the drug showed significant effects in memory and cognitive tests, it did not meet the expected goals, resulting in a 3.9% drop in stock price. Source: Reuters 2. On July 14, Truist Securities upgraded Biogen to a Buy rating, raising the target price to $235, reflecting market optimism regarding its Alzheimer's and immunology pipeline. Analysts believe that upcoming clinical data will act as a catalyst for stock price increases. Source: Investing.com 3. On July 13, the FDA approved a subcutaneous version of Biogen's Alzheimer's treatment Leqembi, developed in collaboration with Eisai, providing a more convenient treatment option and supporting the stock price increase. Source: Dow Jones Newswires Significant progress has been made in Alzheimer's drug development, attracting market attention. AbbVie fell 1.07%. Based on recent news, 1. On July 13, Wells Fargo raised AbbVie's target price from $260 to $295, maintaining an "Outperform" rating. This news boosted market confidence but did not fully offset the overall negative sentiment in the market, leading to a slight decline in stock price. 2. On July 11, UBS raised AbbVie's target price from $230 to $260. Although analysts are generally optimistic, concerns about the overall pharmaceutical industry still exist, affecting stock performance On July 11, the market had high expectations for the second-quarter earnings of biopharmaceutical companies, but AbbVie faced pressure from patent expirations, leading to cautious investor sentiment and downward pressure on its stock price. The pharmaceutical industry as a whole is facing pressure from patent expirations. **Stocks ranked among the top in industry market capitalization** Amgen fell 1.05%. Based on recent key news: 1. On July 14, MarketBeat reported that although Amgen currently holds a "Hold" rating among analysts, top analysts believe there are five stocks that are more worthy of purchase. This news may weaken investor confidence in Amgen, thereby affecting its stock price. 2. On July 13, MarketBeat pointed out that Amgen was not included in the list of five stocks recommended by top analysts, which may further weaken market expectations for its future performance, leading to a decline in its stock price. The market is taking a cautious stance towards the biopharmaceutical industry ### Related Stocks - [GALT.US](https://longbridge.com/en/quote/GALT.US.md) - [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md) - [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [Why Biogen stock topped the market today](https://longbridge.com/en/news/294280002.md) - [Biogen Inc. $BIIB Shares Sold by ADAR1 Capital Management LLC](https://longbridge.com/en/news/294165856.md) - [Biogen (NASDAQ:BIIB) Updates FY 2026 Earnings Guidance](https://longbridge.com/en/news/294199547.md) - [Biogen Q2 revenue beats expectations on strong product demand](https://longbridge.com/en/news/294189729.md) - [Orbimed Advisors LLC Makes New $11.29 Million Investment in Biogen Inc. $BIIB](https://longbridge.com/en/news/293916094.md)